Showing results (1551-1560 of 2,739) with videos related to

Sort By:
Pageof 274
Pharmacogenomics|December 5, 2009
Role of the PACAP-PAC1-DISC1 and PACAP-PAC1-stathmin1 systems in schizophrenia and bipolar disorder: novel treatment mechanisms?Taiichi Katayama, Tsuyoshi Hattori, Kohei Yamada, et al.
Pharmacogenomics|December 19, 2009
Pharmacogenetics in reproductive and perinatal medicineAna Alfirevic, Zarko Alfirevic, Munir Pirmohamed
Pharmacogenomics|November 22, 2005
Flavin-containing monooxygenase genetic polymorphism: impact on chemical metabolism and drug developmentSevasti B Koukouritaki, Ronald N Hines
Pharmacogenomics|November 22, 2005
Pharmacogenomics and drug developmentYingying Guo, Steven Shafer, Paul Weller, et al.
Pharmacogenomics|November 22, 2005
Physiogenomic analysis links serum creatine kinase activities during statin therapy to vascular smooth muscle homeostasisGualberto Ruaño, Paul D Thompson, Andreas Windemuth, et al.
Pharmacogenomics|November 3, 2017
Impact of CYP2D6 and ADRB1 polymorphisms on heart rate of post-PCI patients treated with metoprololXiaofeng Gao, Huan Wang, Hui Chen
Pharmacogenomics|November 3, 2017
Pharmacogenetics of glatiramer acetate therapy for multiple sclerosis: the impact of genome-wide association studies identified disease risk lociOlga Kulakova, Vitalina Bashinskaya, Ivan Kiselev, et al.
Pharmacogenomics|November 3, 2017
Triple-negative breast cancer and the potential for targeted therapyJing-Ru Jhan, Eran R Andrechek
Pharmacogenomics|January 11, 2019
Cost-effectiveness analysis of UGT1A1*6/*28 genotyping for preventing FOLFIRI-induced severe neutropenia in Chinese colorectal cancer patientsXiaoXia Wei, JiaQin Cai, Hong Sun, et al.
Pharmacogenomics|January 11, 2019
Genetic variation of kinases and activation of nucleotide analog reverse transcriptase inhibitor tenofovirAllyson N Hamlin, Joseph Tillotson, Namandjé N Bumpus
Pageof 274